SCHEMBL2574294

SCHEMBL2574294

Cc1nc(Cl)c([N+](=O)[O-])c(NCc2ccccc2)c1C

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.47
MAPT P10636 6/20 0.47
LMNA P02545 5/20 0.46
ALDH1A1 P00352 4/20 0.46
HPGD P15428 3/20 0.46
CYP3A4 P08684 2/20 0.46
MEN1 O00255 1/20 0.46
CYP1A2 P05177 1/20 0.46
CYP2D6 P10635 1/20 0.46
CYP2C9 P11712 1/20 0.46
CRHBP P24387 1/20 0.46
CYP2C19 P33261 1/20 0.46
KMT2A Q03164 1/20 0.46
CRHR2 Q13324 1/20 0.46
HTT P42858 2/20 0.46
EGFR P00533 1/20 0.45
POLB P06746 2/20 0.44
MAPK1 P28482 2/20 0.44
TP53 P04637 1/20 0.43
BLM P54132 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4770133 0.95 SMN1; SMN2 (0.44) SMN1; SMN2MAPTLMNAALDH1A1HPGD
SCHEMBL4776209 0.83 LMNA (0.41) SMN1; SMN2MAPTLMNAALDH1A1HPGD
SCHEMBL212307 0.81 EGFR (0.60) SMN1; SMN2MAPTLMNAALDH1A1HPGD
SCHEMBL4775893 0.80 MAPT (0.48) SMN1; SMN2MAPTLMNAALDH1A1CYP3A4
SCHEMBL13527456 0.78 POLB (0.42) SMN1; SMN2MAPTLMNAALDH1A1HTT
SCHEMBL27614131 0.77 MAPT (0.43) SMN1; SMN2MAPTALDH1A1MEN1KMT2A
SCHEMBL2572685 0.77 SMN1; SMN2 (0.43) SMN1; SMN2MAPTLMNAALDH1A1HPGD
SCHEMBL22898884 0.77 EGFR (0.44) SMN1; SMN2MAPTLMNAALDH1A1HPGD
SCHEMBL29605525 0.77 EGFR (0.44) SMN1; SMN2MAPTLMNAALDH1A1HPGD
SCHEMBL6096912 0.77 ACHE (0.48)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1987030-B1 3 -DEAZAPURINE DERIVATIVES AS TLR7 MODULATORS PFIZER LTD (GB) 2011-11-09 EP disclosed
US-7691877-B2 Pharmaceuticals PFIZER INC. (US) 2010-04-06 US disclosed
CN-101384593-A 3-deazapurine derivatives as tlr7 modulators PFIZER LTD (GB) 2009-03-11 CN disclosed
EP-1987030-A1 3 -DEAZAPURINE DERIVATIVES AS TLR7 MODULATORS Pfizer Limited (GB) 2008-11-05 EP disclosed
WO-2007093901-A1 3 -DEAZAPURINE DERIVATIVES AS TLR7 MODULATORS PFIZER LIMITED (GB) 2007-08-23 WO disclosed
US-20070197478-A1 NOVEL PHARMACEUTICALS PFIZER LIMITED 2007-08-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070197478-A1 NOVEL PHARMACEUTICALS TLR3, HAVCR2, TLR9 SMN1; SMN2 4767/4885MAPT 4363/4885LMNA 4120/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.